会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • ANTI-INFLAMMATORY GLUCOCORTICOIDS
    • 抗炎药物葡萄球菌
    • WO2005028495A1
    • 2005-03-31
    • PCT/EP2004/010779
    • 2004-09-22
    • GLAXO GROUP LIMITEDBIGGADIKE, KeithWEINGARTEN, Gordon, Gad
    • BIGGADIKE, KeithWEINGARTEN, Gordon, Gad
    • C07J71/00
    • C07J71/0031C07J71/00
    • A compound of formula (I) wherein R 1 and R 2 are the same or different and each represents hydrogen, halogen or a methyl group; R 3 represents H, Cl, F, OH OR OC(O)R 6 ; R 4 represents hydrogen or methyl, R 5 represents -(CH 2 ) n -CH=CH) m -Cycl or -(CH 2 ) n -(CH=CH) m -Ar or cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl; n represents 0, 1 or 2; m represents 0 or 1; R 6 represents H, C 1-8 alkyl; and formula (b) represents a single or a double bond; including pharmaceutically acceptable esters, amides and carbamates thereof, salts thereof, solvates thereof, and solvates of such pharmaceutically acceptable esters, amides, carbamates and salts.
    • 式(I)的化合物,其中R 1和R 2相同或不同,各自表示氢,卤素或甲基; R 3表示H,Cl,F,OH或OC(O)R 6; R 4表示氢或甲基,R 5表示 - (CH 2)n -CH = CH)m- Cycl或 - (CH 2)n - (CH = CH)m-Ar或环丙基,环丁基,环戊基,环己基,环庚基或环辛基; n表示0,1或2; m表示0或1; R 6表示H,C 1-8烷基; 式(b)表示单键或双键; 包括其药学上可接受的酯,酰胺和氨基甲酸酯,其盐,溶剂合物和这些药学上可接受的酯,酰胺,氨基甲酸酯和盐的溶剂合物。
    • 5. 发明申请
    • THIAZOLIDINE DERIVATIVES AND THEIR USE AS ANTI-VIRAL COMPOUNDS
    • 噻唑烷衍生物及其作为抗病毒化合物的用途
    • WO1993001174A1
    • 1993-01-21
    • PCT/EP1992001494
    • 1992-07-03
    • GLAXO GROUP LIMITEDKITCHIN, JohnHOLMES, Duncan, StuartHUMBER, David, CedricSTORER, RichardDOLAN, Simon, CharlesHANN, Michael, MenteithMCMEEKIN, PeterMURRAY-RUST, PeterPATEL, BinakumariWEINGARTEN, Gordon, Gad
    • GLAXO GROUP LIMITED
    • C07D217/06
    • C07D417/12C07D277/06C07D417/14
    • The present invention provides compounds of formula (I), wherein R is hydrogen, alkyl or CH2alkyl where the alkyl portion is substituted by OH; A represents either a group CHR CHR OH or a group (II), where R is hydrogen, alkyl, cycloalkylalkyl or Aralkyl, R is hydrogen, alkyl, cycloalkylalkyl, aralkyl, CHR CONR R (where R is hydrogen, alkyl, cycloalkylalkyl or Aralkyl, R is hydrogen or methyl and R is hydrogen, alkyl optionnally substituted by one or two hydroxyl groups, aryl, heteroaryl, cycloalkylalkyl, Aralkyl wherein the alkyl portion is optionnally substituted by hydroxymethyl, or Hetalkyl) or CHR NHCOR (where R is alkyl, cycloalkylalkyl or an aralkyl), R is alkoxy or NR R (where R is hydrogen or methyl and R is hydrogen, alkyl, aryl, aralkyl or cycloalkylalkyl); X is a group -CHR (CHR )r(CHR )sCHR -, where R and R are hydrogen, r is 1, s is zero and R is hydroxyl or hydroxymethyl, or R and R are hydrogen, r and s are 1 and R and R are each hydrogen or hydroxyl provided that at least one of R and R is hydroxyl, or one of R and R is hydrogen and the other is hydroxymethyl and r and s are zero; useful in chemotherapy, particularly of viral infections.
    • 本发明提供式(I)化合物,其中R 1是氢,烷基或C 2烷基,其中烷基部分被OH取代; A代表基团CHR 21 CHR 22 OH或基团(II),其中R 21是氢,烷基,环烷基烷基或芳烷基,R 22是氢,烷基,环烷基烷基,芳烷基,CHR 24 R CONR 25 R 26(其中R 24是氢,烷基,环烷基烷基或芳烷基,R 25是氢或甲基,R 26是氢,烷基选择性地被一个或两个羟基取代 ,芳基,杂芳基,环烷基烷基,芳烷基,其中烷基部分选择性地被羟甲基或Hetalkyl取代)或CHR 24 NHCOR 27(其中R 27是烷基,环烷基烷基或芳烷基),R 23是 烷氧基或NR 28 R 29(其中R 28是氢或甲基,R 29是氢,烷基,芳基,芳烷基或环烷基烷基); X是基团-CHR 30(CHR 31)r(CHR 32)s CHR 33,其中R 30和R 33是氢,r是1,s是0,R 31是羟基或羟甲基,或R 30和R 33是氢,r和s是1,R 31和R 32各自是氢或羟基,条件是R 31中至少有一个 且R 32为羟基,R 30和R 33之一为氢,另一个为羟甲基,r和s为0; 可用于化疗,特别是病毒感染。
    • 6. 发明申请
    • THIAZOLIDINE DERIVATIVES AND THEIR USE IN THERAPY
    • 噻唑啶衍生物及其在治疗中的应用
    • WO1992020665A1
    • 1992-11-26
    • PCT/GB1992000840
    • 1992-05-08
    • GLAXO GROUP LIMITEDHUMBER, Dai, CedricWEINGARTEN, Gordon, GadSTORER, RichardKITCHIN, JohnHANN, Michael, Menteith
    • GLAXO GROUP LIMITED
    • C07D277/06
    • C07D417/14C07D277/06C07D499/00
    • The present invention provides compounds of formula (I), wherein x is zero, 1 or 2; R and R are each independently hydrogen, C1-4alkyl or CH2C1-3alkyl where the C1-3alkyl portion is substituted by OH; R , R , R and R are each independently hydrogen, methyl, ethyl, CH2OH,CH2NH2 or COOH when x is zero, or R , R , R and R are each independently hydrogen, methyl or CH2OH when x is 1 or 2; R and R are each independently hydrogen, C1-10alkyl, C3-8cycloalkyl, ArC1-4alkyl, HetC1-4alkyl, COAr, COHet, COCH2R , COCH(OH)Ar, COCH(OH)Het, COCH=CHPh, COR , CO2CH2Ar, CO2CH2Het, SO2Ar, SO2Het,SO2CH2R , SO2CH=CHPh or SO2R [where R and R each independently represent hydrogen, C1-6alkyl, aryl, heteroaryl, ArC1-4alkyl, HetC1-4alkyl, aryloxy, heteroaryloxy, C3-8cycloalkyl, C3-8cycloalkylC1-4alkyl, (CH2)nCO2R (where n is zero or 1 and R is hydrogen or C1-6alkyl), (CH2)mNR R (where m is zero, 1, 2, 3, 4 or 5 and R are each independently hydrogen or C1-4alkyl or together with the nitrogen atom to which they are attached form a saturated heterocyclic amino group), and R and R each independently represent C3-8cycloalkyl substituted by phenyl]; R and R are each independently hydrogen, C1-6alkyl, COOR (where R is hydrogen, C1-6alkyl or ArC1-4alkyl) or CONR R [where R is hydrogen or C1-4alkyl and R is hydrogen, OH, aryl, heteroaryl, ArC1-4alkyl (wherein the C1-4alkyl portion is optionally substituted by hydroxymethyl), HetC1-4alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-4alkyl, (CH2pR (where p is zero or 1 and R is CF3 or CO2R where R is hydrogen or C1-6alkyl), (CH2)qNR R (where q is zero, 1, 2, 3, 4, or 5 and R and R are each independently hydrogen, C1-4alkyl or aryl or together with the nitrogen atom to which they are attached form a saturated heterocyclic amino group), CHArCO2R , CHHet CO2R (where R and R are each independently hydrogen or C1-6alkyl) or C1-6alkyl optionally substituted by OH, or R and R together with the nitrogen atom to which they are attached form a saturated heterocyclic amino group]; R and R are each independently hydrogen, hydroxy or acetoxy; and physiologically acceptable salts and solvates thereof. Also described are the use of the compounds as antiviral agents, pharmaceutical compositions containing them and methods for their preparation.
    • 本发明提供式(I)化合物,其中x为0,1或2; R 1和R 6各自独立地为氢,C 1-4烷基或C 2 -C 1-3烷基,其中C 1-3烷基部分被OH取代; 当x为零时,R 2,R 3,R 4和R 5各自独立地为氢,甲基,乙基,CH 2 OH,CH 2 NH 2或COOH,或R 2,R 3,R 当x为1或2时,R 4和R 5各自独立地为氢,甲基或CH 2 OH; R 7和R 9各自独立地为氢,C 1-10烷基,C 3-8环烷基,Ar C 1-4烷基,Het C 1-4烷基,COAr,COHet,COCH 2 R 13,COCH(OH)Ar,COCH(OH)Het ,COCH = CHPh,COR 14,CO 2 CH 2 Ar,CO 2 CH 2 Het,SO 2 Ar,SO 2 Het,SO 2 CH 2 R 15,SO 2 CH = CHPh或SO 2 R 16 [其中R 13和R 15各自独立地表示氢,C 1-6烷基 ,芳基,杂芳基,ArC 1-4烷基,HetC 1-4烷基,芳氧基,杂芳氧基,C 3-8环烷基,C 3-8环烷基C 1-4烷基,(CH 2)n CO 2 R 17(其中n为0或1,R 17为氢或C 1 烷基),(CH 2)m NR R 18 R(其中m为0,1,2,3,4或5,R 19各自独立地为氢或C 1-4烷基或与氮原子一起 它们连接形成饱和杂环氨基),R 14和R 16各自独立地表示被苯基取代的C 3-8环烷基; R 8和R 10各自独立地为氢,C 1-6烷基,COOR 20(其中R 20为氢,C 1-6烷基或ArC 1-4烷基)或CONR 21 R 22 [其中 R 21是氢或C 1-4烷基,R 22是氢,OH,芳基,杂芳基,ArC 1-4烷基(其中C 1-4烷基部分任选被羟甲基取代),HetC 1-4烷基,C 3-8环烷基,C 3 -8环烷基C 1-4烷基,(CH 2 p R 23)(其中p为0或1,R 23为CF 3或CO 2 R 24,其中R 24为氢或C 1-6烷基),(CH 2)q NR R R <26>(其中q为零,1,2,3,4或5,R 25和R 26各自独立地为氢,C 1-4烷基或芳基,或与它们相连的氮原子一起 形成饱和杂环氨基),CHArCO 2 R 27,CHHet CO 2 R 28(其中R 27和R 28各自独立地为氢或C 1-6烷基)或任选被OH取代的C 1-6烷基, 21>和R 22与它们所连接的氮原子一起形成饱和杂环氨基]; R 11和R 12各自独立地为氢 羟基或乙酰氧基; 及其生理上可接受的盐和溶剂合物。 还描述了化合物作为抗病毒剂的用途,含有它们的药物组合物及其制备方法。